NDT Advance Access published online on May 5, 2004
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh219
© 2004 by European Renal Association - European Dialysis and Transplant Association
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medical Faculty University of Cologne, Department of Internal Medicine I, Cologne General Hospital, Merheim Medical Center, Cologne, Germany
* To whom correspondence should be addressed. E-mail: oliver.gross{at}uni-koeln.de.
Background. Several studies have shown antifibrotic effects of angiotensin converting enzyme (ACE) inhibitors as well as of angiotensin receptor 1 (AT1) antagonists, however, prospective trials with clinical end points comparing these effects do not exist. COL4A3-/- mice develop a non-hypertensive progressive renal fibrosis. We used this animal model to compare the potential of ACE inhibitor vs AT1 antagonist to prevent renal fibrosis irrespective of blood pressure-dependent involvement by the renin system. Methods. COL4A3-/- mice were treated with placebo, ramipril or candesartan. Blood pressure, proteinuria, serum urea and lifespan were monitored. Renal matrix was characterized by immuno-histochemistry, light and electron microscopy. Further biochemical analysis was provided using cDNA microarray and western blot techniques. Results. Untreated mice died of renal failure after 71±6 days. Ramipril and candesartan both delayed onset and reduced the extent of proteinuria. Both had minor effects on blood pressure and postponed onset of uraemia. Ramipril increased lifespan by 111% to 150±21 days (P<0.01), whereas candesartan resulted in only a 38% prolongation to 98±16 days (P<0.01). Ramipril reduced glomerular and tubulo-interstitial fibrosis and numbers of activated fibroblasts to a greater extent than candesartan. Microarray and western blot analysis revealed a higher antifibrotic potential of ramipril in terms of downregulation of TGF Conclusions. The results indicate an antifibrotic, nephroprotective effect of ACE inhibitors and AT1 antagonists in an animal model of progressive renal fibrosis. The greater antifibrotic effect of ramipril at the maximal therapeutic doses employed may not be explained by different antiproteinuric or blood pressure lowering properties, but by--in contrast to candesartan--its ability to hinder the proinflammatory, profibrotic activation of the angiotensin receptor 2.
Accepted February 13, 2004
Original Article
Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis
2 Department of Anatomy I, The Medical Faculty, University of Cologne, Cologne, Germany
3 Center for Biochemistry, The Medical Faculty, University of Cologne, Cologne, Germany
Abstract 
, connective tissue growth factor, metalloproteinases and extracellular matrix proteins.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. I. Ager, J. Neo, and C. Christophi The renin-angiotensin system and malignancy Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Katayama, M. Kawano, I. Naito, H. Ishikawa, Y. Sado, N. Asakawa, T. Murata, K. Oosugi, M. Kiyohara, E. Ishikawa, et al. Irradiation Prolongs Survival of Alport Mice J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1692 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Omasu, T. Oda, M. Yamada, N. Yoshizawa, K. Yamakami, Y. Sakurai, and S. Miura Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1292 - F1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Beirowski, M. Weber, and O. Gross Chronic Renal Failure and Shortened Lifespan in COL4A3+/- Mice: An Animal Model for Thin Basement Membrane Nephropathy J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1986 - 1994. [Abstract] [Full Text] [PDF]
|
|